Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at StockNews.com

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research note released on Tuesday.

COLL has been the subject of a number of other reports. Needham & Company LLC reissued a buy rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. Jefferies Financial Group reiterated a hold rating and issued a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Truist Financial lifted their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a buy rating in a research report on Monday, February 26th. Finally, Piper Sandler reiterated an overweight rating and issued a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $39.00.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $35.84 on Tuesday. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. The business has a fifty day simple moving average of $37.06 and a two-hundred day simple moving average of $31.18. Collegium Pharmaceutical has a 1 year low of $20.83 and a 1 year high of $40.95. The company has a market capitalization of $1.17 billion, a P/E ratio of 30.37 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The business had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. On average, analysts expect that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in COLL. New York State Teachers Retirement System lifted its stake in Collegium Pharmaceutical by 6.6% during the first quarter. New York State Teachers Retirement System now owns 13,298 shares of the specialty pharmaceutical company’s stock worth $516,000 after purchasing an additional 824 shares during the last quarter. Nations Financial Group Inc. IA ADV bought a new stake in Collegium Pharmaceutical during the first quarter worth about $386,000. HighPoint Advisor Group LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $514,000. Penn Capital Management Company LLC bought a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $9,755,000. Finally, Avidity Partners Management LP lifted its stake in shares of Collegium Pharmaceutical by 3.2% in the 4th quarter. Avidity Partners Management LP now owns 361,363 shares of the specialty pharmaceutical company’s stock valued at $11,123,000 after acquiring an additional 11,163 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.